Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

People exposed to wood and tobacco smoke are at greater risk for developing COPD

People who are consistently exposed to both wood smoke and tobacco smoke are at a greater risk for developing chronic obstructive pulmonary disease and for experiencing more frequent and severe symptoms of the disease, as well as more severe airflow obstruction, than those who are exposed to only one type of smoke, according to the results of a new population-based study conducted by researchers in Colombia.

21 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

Study examines self-management support in primary care

The processes to allow people to self-manage their own illness are not being used appropriately by health professionals to the benefit of their patients, new research suggests.

18 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

American Association for Respiratory Care names Jefferson a Quality Respiratory Care Institution

Thomas Jefferson University Hospital was recently bestowed the title of "Quality Respiratory Care Institution" for 2013 by the American Association for Respiratory Care.

16 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

COPD patients with allergic phenotype have increased risk of lower respiratory symptoms, exacerbations

Patients with chronic obstructive pulmonary disease (COPD) who also have allergic disease have higher levels of respiratory symptoms and are at higher risk for COPD exacerbations, according to a new study from researchers at Johns Hopkins University in Baltimore.

10 May 2013

Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults

Research from the Regenstrief Institute, the Indiana University Center for Aging Research and Wishard-Eskenazi Health on medications commonly taken by older adults has found that drugs with strong anticholinergic effects cause cognitive impairment when taken continuously for as few as 60 days.

8 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

GOLD predicts mortality in COPD

The Global Initiative for Chronic Obstructive Lung Disease classification of chronic obstructive pulmonary disease predicts mortality better than the 2011 ABCD scoring system, report Norwegian researchers.

30 Apr 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

30 Apr 2013

Schizophrenia cardiovascular risk under-recognized in primary care

UK researchers have found that despite being a major contributor to premature deaths among patients with schizophrenia, cardiovascular disease is less likely to be recorded on their primary care records than those of people without schizophrenia.

30 Apr 2013

COPD-asthma overlap ‘needs greater recognition’

More attention should be given to patients who have chronic obstructive pulmonary disease and concomitant asthma, after a study showed that nearly one-fifth of patients with COPD fall into this subtype.

30 Apr 2013

IP-10 and neopterin show promise as biomarkers for lung disease exacerbations

Australian researchers have identified interferon-γ inducible protein-10 and neopterin as promising sputum markers of acute exacerbations of obstructive lung disease.

29 Apr 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

29 Apr 2013

UK’s health performance: an interview with Prof. Murray, University of Washington

Rates of premature mortality in the UK have been falling steadily, but the pace of decline is not as fast as in many other high-income countries, such as Australia. In that sense, the UK lags behind.

29 Apr 2013

Schizophrenia cardiovascular risk under-recognized in primary care

25 Apr 2013

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013

COPD phase III study by Almirall and Forest Laboratories announces positive results

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

16 Apr 2013

ACOEM provides tools, resources to help employers identify and respond to impact of COPD

Awareness campaign for the workplace provides tools and information on preventing and managing chronic obstructive pulmonary disease - the third leading cause of death in the U.S.

12 Apr 2013

Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

People exposed to wood and tobacco smoke are at greater risk for developing COPD

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Study examines self-management support in primary care

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

American Association for Respiratory Care names Jefferson a Quality Respiratory Care Institution

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

COPD patients with allergic phenotype have increased risk of lower respiratory symptoms, exacerbations

Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

GOLD predicts mortality in COPD

Specific inflammatory pattern found in patients with pneumonia and COPD

Schizophrenia cardiovascular risk under-recognized in primary care

COPD-asthma overlap ‘needs greater recognition’

IP-10 and neopterin show promise as biomarkers for lung disease exacerbations

Specific inflammatory pattern found in patients with pneumonia and COPD

UK’s health performance: an interview with Prof. Murray, University of Washington

Schizophrenia cardiovascular risk under-recognized in primary care

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

COPD phase III study by Almirall and Forest Laboratories announces positive results

ACOEM provides tools, resources to help employers identify and respond to impact of COPD

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in